The trading price of 180 Life Sciences Corp. (NASDAQ:ATNF) closed lower on Friday, Feb 19, closing at $5.2, -13.46% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $4.3600 and $5.0900. The company’s P/E ratio in the trailing 12-month period was 0, while its 5Y monthly beta was -0.66. In examining the 52-week price action we see that the stock hit a 52-week high of $11.5 and a 52-week low of $1.9. Over the past month, the stock has gained 30.43% in value.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of 180 Life Sciences Corp. no upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest ATNF has a 50% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
To see how 180 Life Sciences Corp. stock has been performing in comparison to its peers in the industry, here are the numbers: ATNF stock’s performance was -13.46% in the latest trading, and -56.18% in the past year, while Bristol-Myers Squibb Company (BMY) has traded -0.69% on the day and positioned -7.01% lower than it was a year ago. Another comparable company Amgen Inc (AMGN) saw its stock close -0.36% lower in the most recent trading session but was up +4.3% in a year. Furthermore, Gilead Sciences Inc (GILD) showed a decline of -13.46% on the day while its price kept declining at -56.18% over the past year. 180 Life Sciences Corp. has a P/E ratio of 0, compared to Bristol-Myers Squibb Company’s 0 and Amgen Inc’s 18.81. Also in last trading session, the S&P 500 Index has soared -0.19%, while the Dow Jones Industrial also saw a negative seesion, down 0% on the day.
An evaluation of the daily trading volume of 180 Life Sciences Corp. (NASDAQ:ATNF) indicates that the 3-month average is 1.74 Million. However, this figure has increased over the past 10 days to an average of 2.06 Million.
Currently, records show that 21.51 Million of the company’s shares remain outstanding. According to Thomson Reuters data, insiders hold 57.18% of outstanding shares, whereas institutions hold 4.81%. The stats also highlight that short interest as of January 28, 2021, stood at 298.26 Million shares, resulting in a short ratio of 0.19 at that time. From this, we can conclude that short interest is 1.39% of the company’s total outstanding shares. It is noteworthy that short shares in January were up slightly from the previous month’s figure, which was 140.49 Million. However, since the stock’s price has seen +64.84% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.